Full-Time

Production Associate

PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

No salary listed

Melbourne VIC, Australia

In Person

On-site in Moorabbin, Australia; must be eligible to work in Australia.

Bachelor's

Category
Operations & Logistics (1)

Get referred to PCI Pharma Services

See people who can refer or advise you

Requirements
  • Previous industry experience in Pharmaceuticals and/or GMP environment
  • Bachelor of Science, Pharmacy or related Discipline
  • Excellent English written and verbal skills with good attention to detail
  • Scientific experience
  • Previous industry manufacturing/labelling experience
  • High level of professionalism, ethics, quality of work, communication and responsiveness at all times
  • Positive, ‘can-do’ attitude, embraces and ‘lives’ PCI’s Vision and Values
  • Analytical thinker and solution finder/problem solver
  • Attention to detail
  • Collaborative, team player
  • Objective and robust decision maker
  • Trusting and trustworthy
  • Conscientious and diligent
Responsibilities
  • The Production Associate facilitates all steps involved in label text approval and printing, and packaging and labelling activities including obtaining approvals and ensuring that the label text meets TGA and/or applicable country regulatory requirements
  • ensuring that the printing of labels is in accord with applicable GMP requirements and as per PCI SOPs
  • completing campaigns in accordance with Batch Records, PCI SOPs, Work Instructions etc. and maintains EHS requirements
  • cleaning and maintenance verification for facility and equipment
  • ensuring all required information for label drafting and label printing received from Project Manager are complied with and executed accordingly
  • ensuring label text for each project is compliant and ready to be approved by the client/sponsor.
  • performing day-to-day packaging and labelling activities in the production facility as scheduled by the Production Associate Manager.
  • completing batch records accurately and concurrent with packaging and labelling activities and ensuring all steps listed are completed.
  • preparing for line clearance, and removal of any production waste/rubbish once production is completed. Production Associates may be requested to perform line clearance sign off.
  • assisting in maintaining of the cGMP facility licence and may be required to assist in facility audits (e.g. PCI internal audits and audits conducted by Clients/Sponsors and Regulatory Authorities).
  • Undergoing practical training and be involved in procedural updates and provide input for process designs.
  • Completing company training requirements in accordance with curricula and other training as may be required (e.g. completion of training when SOPs, Work Instructions etc. are updated or new SOPs, Work Instructions etc. are issued that are applicable to production)
  • Facilitate all steps leading to label text approval, including preparing the draft label text for review/approval by PCI and Client
  • Liaise with all appropriate PCI employees to facilitate the preparation of draft/final label text, including label design decisions
  • Ensure that the label text meets PIC/s (Annex-13) and TGA regulatory requirements and in collaboration with the client the applicable country regulatory requirement
  • Incorporating variable text information e.g. Batch number, Product Code, Kit Number (as applicable), Retest Date etc as per client requirement
  • Manage kit lists in accordance with applicable procedures or work instructions
  • Liaise with company (or client) approved third party translators as may be required
  • Ensure that the printing of labels is conducted in a GMP compliant manner, using the correct base label and ribbon combination, that printing is in accordance with applicable PCI SOP(s) and that the appropriate PCI Forms/Records are completed and retained in the designated locations
  • Confirm that the combination of base label and ribbon will deliver a printed label that is fit for purpose for the intended substrate (packaging material) and storage conditions, and for conducting the appropriate rub/smudge/scratch adherence test on labels prior to issuance
  • Ensure that the quality of the printed labels obtain Quality approval prior to the labels being issued to production
  • Provide printed labels to be ready for production in a timely manner, supported by the applicable records/forms
  • Ensure that label printing is undertaken in such a way that there is no risk of mix-up, ensuring line clearance is undertaken prior to commencing each printing episode
  • Deface any printed labels that are damaged/not required during the printing process
  • Reconcile unprinted labels (blank labels) and printed labels that are to be used or rejected at the end of the print run.
  • Evaluate options for additional/replacement hardware as applicable
  • Liaise with external printers to coordinate printing of labels
  • Ensuring the required Batch Record has been approved and QA issued prior to use
  • Ensuring the required packaging room is ready for use and that appropriate Room logs and registers are completed
  • Following the company gowning and hygiene requirements
  • Verifying the picked released stock and equipment for labelling of clinical supplies and packaging and assembling kits of finished products in accordance with the Batch Records.
  • Ensuring that samples are taken in accordance with the batch record instructions (e.g. retention samples).
  • Reviewing production batch records and ensuring that these are completed and signed prior to Production Senior Associate review.
  • Ensuring that all deviations are reported to the Production Senior Associate or Production Associate Manager.
  • Making sure that production facilities are clean and when appropriate, disinfected.
  • Cleaning of equipment in accordance with SOPs.
  • Removing waste materials and rubbish from the packaging facilities and placing in the correct bins.
  • Verify calibrations of equipment prior to use and records kept/registers completed.
  • Ensuring that the premises and equipment are maintained and relevant records kept.
  • Reviewing labels and randomisation lists against label approval forms and master randomisation lists prior to commencing batch manufacture.
  • Preparing, reviewing and maintaining SOPs relevant to the Production facility.
  • Participating in PCI internal audits and third-party audits and assist in responding to audit findings and product complaints/recalls as may be required.
  • Follow company EHS requirements
  • Implement continuous improvement actions as may be appropriate
  • Completion additional tasks as allocated by the Senior Production Associates or Production Associate Manager
  • Assisting other departments as required.

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Get referred to PCI Pharma Services

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 2026 $1 billion spend expands RTU syringes, cartridges, autoinjectors, and lyophilization.
  • Bedford reached full-scale production in April, adding 33 million annual vial capacity.
  • August 2026 Bedford job fairs show active hiring despite heavy capex.

What critics are saying

  • 2028 San Diego line delays revenue while rivals capture GLP-1 and biologics demand.
  • McCary v. PCI Pharma Services, filed July 2026, brings fresh employment litigation.
  • A major sterile-fill recall would destroy trust with pharma clients and regulators.

What makes PCI Pharma Services unique

  • PCI combines sterile fill-finish, device assembly, packaging, and development across U.S. and Europe.
  • Bedford and San Diego now anchor high-potent, lyophilization, and prefilled syringe capacity.
  • 2025 Bain, Kohlberg, and Mubadala backing funds inorganic expansion under Salim Haffar.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

Nikkei
May 20th, 2026
Atsushi Watanabe to become president of PCI Holdings

Atsushi Watanabe to become president of PCI Holdings May 20, 2026 17:59 Atsushi Watanabe: Graduated from Shinshu University's Faculty of Economics in 1986 (Showa 61). Joined Kyodo VAN (now SCSK). Became president of SCSK Serviceware in 2022 and director of Lester in April 2026. Born in Hyogo Prefecture. Aged 64. (Will become president on June 23. Current president Kensaku Morishita will become senior managing director) All articles freely readable Paid members get first month free AI trained on Nikkei online edition articles

Megaproject
Apr 29th, 2026
PCI Pharma Services makes $1B investment to scale injectable manufacturing, device assembly.

PCI Pharma Services makes $1B investment to scale injectable manufacturing, device assembly. By Pharma Manufacturing - Facilities - April 29, 2026 - 5 min Philadelphia-based PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has announced a series of infrastructure investments aimed at expanding its sterile fill-finish and advanced drug delivery capabilities, as demand for injectable therapies and supply chain resilience continues to reshape the pharmaceutical industry. The investments are part of a broader commitment exceeding $1 billion across PCI's U.S. and European operations, meant to reinforce the CDMO's ability to support drug product development and manufacturing, clinical trial supply, and drug-device combination assembly from clinical stages through commercial launch. Central to the announcement is a $100 million investment at PCI's San Diego campus, where the company will install a high-speed isolator filling line for ready-to-use (RTU) prefilled syringes and cartridges. The new line, expected to be operational in the first half of 2028, will more than double the site's existing syringe and cartridge capacity, which already supports more than 45 FDA-approved products. The San Diego campus also hosts large-scale aseptic filling for prefilled syringes and cartridges, alongside specialized capabilities in oligonucleotides, peptides, complex formulations, and lyophilization for injectables such as nanoparticles, mRNA, monoclonal antibodies, proteins, and highly potent products. Chief Commercial Officer Tim Roberts told Pharma Manufacturing these investments reflect a broader shift toward injectable drug formats, driven in part by the rapid rise of GLP-1 therapies and other biologics that are increasingly administered outside traditional healthcare settings. This trend is also extending into more complex therapeutic areas, including oncology and central nervous system (CNS) disorders, making drug-device combinations more central to how therapies are developed and delivered, according to Roberts. "Now those next-generation medicines for oncology, CNS, and rare diseases no longer need to be delivered strictly by healthcare professionals," says Roberts. "That accepted technology of pens, autoinjectors, and on-body devices is now being recognized by pharma companies and payers as the forward modality of how these lifesaving medicines can be delivered in a much more patient-centric way." In parallel, PCI's Bedford, New Hampshire site is commissioning a GMP-ready isolator vial and lyophilization line capable of producing batches of up to 300,000 vials at 400 units per minute - equating to approximately 33 million units annually - following the start of full-scale production in April. The campus will also bring online a customer-dedicated high-potent sterile fill-finish line, according to the company. Both sites are also being outfitted with advanced automated visual inspection (AVI) systems for sterile fill-finish applications. According to Roberts, these systems enhance defect detection - including particulates and cosmetic issues - while enabling rapid, highly accurate inspection of both containers and drug products, helping expand capacity without compromising quality. PCI's U.S.-based AVI infrastructure includes annual accommodation for 40 million blister units, 70 million bottles, and 75 million vials. "It can do these things very quickly and very accurately," Roberts said of the AVI systems. "In investing in AVI systems to this degree, PCI is furthering its ability to have ample room without sacrificing mission-critical quality control." The company has also committed to multiple buildouts of autoinjector and drug-device combination assembly infrastructure, in partnership with leading device manufacturers, at its campuses in Philadelphia and Rockford, Illinois. These upgrades are being introduced in phases over the next six months and are designed to expand both capacity and operational scale of its clinical-through-commercial capabilities. PCI plans to add a third autoinjector assembly line in 2027, which will bring its total U.S. capacity for autoinjector and device assembly to more than 250 million units annually. The lines are designed for high-speed, flexible manufacturing, with the ability to support multiple device formats, while dedicated prefilled syringe safety device capabilities add labeling and secondary packaging options. That growth aligns with what Roberts describes as a clear shift across the development pipeline, with more clinical programs - and ultimately commercial products - moving toward delivery formats such as prefilled syringes, pens, and autoinjectors. These systems support self-administration and are also enabling more decentralized clinical trial models, reducing the need for frequent site visits and potentially improving patient participation and retention. PCI's integrated model, spanning prefilled syringe manufacturing through final device assembly and packaging, is designed to support that continuity. The company's Packaging Centers of Excellence in Philadelphia and Rockford provide capacity for both oral solid dose and injectable products, along with cold chain storage and the ability to rapidly support programs at clinical or commercial scale. Across the two sites, available capacity includes approximately 40 million blister units, 70 million bottles, and 75 million vials annually. In conjunction with expanding its manufacturing platform, PCI is also investing in dedicated Development Centers of Excellence (CoE) in Bedford, New Hampshire, and León, Spain. These centers will support a range of development activities, including lyophilization, formulation, analytical services, drug-device combination development, long-acting injectables, and ophthalmic products, according to the company. The CoEs are designed to handle both highly potent and non-potent, small-molecule and biologic modalities across vials, prefilled syringes, and cartridges. The Bedford Development CoE is expected to be operational this May, with the León site slated for June. Andy Lundin has more than 10 years of experience in business-to-business publishing producing digital content for audiences in the medical and automotive industries, among others. He currently works as Senior Editor for Pharma Manufacturing and is responsible for feature writing and production of the podcast. His prior publications include MEDQOR, a real-time healthcare business intelligence platform, and Bobit Business Media. Andy graduated from California State University-Fullerton in 2014 with a B.A. in journalism. He lives in Long Beach, California. Recent Comments

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.